{
    "pmcid": "10986514",
    "qa_pairs": {
        "What diagnostic tool was developed using nanobodies in the study?": [
            "A nanobody-based detection assay using NanoLuc luciferase fragments",
            "A nanobody-based ELISA test for spike protein detection",
            "A nanobody-based lateral flow assay for rapid testing",
            "A nanobody-based PCR assay for viral RNA detection"
        ],
        "What is the primary target for the engineered nanobodies discussed in the paper?": [
            "The SARS-CoV-2 spike protein",
            "The SARS-CoV-2 nucleocapsid protein",
            "The SARS-CoV-2 membrane protein",
            "The SARS-CoV-2 envelope protein"
        ],
        "What was the observed potency of the engineered nanobodies against the Alpha and Delta variants of SARS-CoV-2?": [
            "IC50 values as low as 50 pM",
            "IC50 values as low as 500 pM",
            "IC50 values as low as 5 nM",
            "IC50 values as low as 50 nM"
        ],
        "Which mutations in the spike protein were specifically assessed for their impact on nanobody binding and neutralization efficacy?": [
            "K417N, E484K, and N501Y",
            "D614G, P681R, and T478K",
            "L452R, T20N, and A222V",
            "Q677H, S477N, and Y144del"
        ],
        "Which nanobody was found to have significantly reduced binding affinity due to the E484K mutation?": [
            "Tri-Ty1",
            "H11-H4",
            "MR17-K99Y",
            "VHH V"
        ]
    }
}